Tc-99m MAG3
Updates to Article Attributes
Tc-99m MAG3 (mercaptoacetyltriglycine) is one of the technetium radiopharmaceuticals used in renal imaging. Due to favourable energy and dosimetric characteristics, MAG3 radiolabeled with technetium has replaced the iodide-131 Hippuran for the study of renal function (tubular secretion physiology) 7.
Characteristics
photon energy: 140 KeV
physical half-life: 6 hours
biological half-life: 4 hours
technetium oxidation state: +5
normal distribution: kidneys (100%)
-
pharmacokinetics:
uptake by tubular secretion (97%)
first pass filtration 60%
excretion: renal via both glomerular filtration and tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to DTPA scan
target organ: bladder
-
miscellaneous facts
good quality images with renal insufficiency
by giving captopril, MAG3 plasma clearance decreases in hypertensive patients with renal artery stenosis but increases in patients without renal artery stenosis
cannot measure GFR as it is cleared almost entirely by tubular secretion
during labelling, MAG3 is heated to remove S-benzoyl group. The S-benzoyl group is important to maintain the stability of the compound during storage conditions 8.
Uses, doses and timings
-
renal study
adult dose: 296 MBq (8 mCi) IV
paediatric dose: 3.7 MBq/kg (0.10 mCi/kg) (minimum: 14.8 MBq (0.4 mCi)) 5
60-sec flow study; then every 5 min for 25 min
-<p><strong>Tc-99m MAG3 (mercaptoacetyltriglycine)</strong> is one of the <a href="/articles/technetium-agents">technetium radiopharmaceuticals</a> used in renal imaging. Due to favourable energy and dosimetric characteristics, MAG3 radiolabeled with technetium has replaced the <a href="/articles/iodide-131-hippuran">iodide-131 Hippuran</a> for the study of renal function (tubular secretion physiology) <sup>7</sup>.</p><h4>Characteristics</h4><ul>-<li>photon energy: 140 KeV</li>-<li>physical half-life: 6 hours</li>-<li>biological half-life: 4 hours</li>-<li>technetium oxidation state: +5</li>-<li>normal distribution: kidneys (100%)</li>-<li>pharmacokinetics:<ul>-<li>uptake by tubular secretion (97%)</li>-<li>first pass filtration 60%</li>- +<p><strong>Tc-99m MAG3 (mercaptoacetyltriglycine)</strong> is one of the <a href="/articles/technetium-99m-agents">technetium radiopharmaceuticals</a> used in renal imaging. Due to favourable energy and dosimetric characteristics, MAG3 radiolabeled with technetium has replaced the <a href="/articles/iodide-131-hippuran">iodide-131 Hippuran</a> for the study of renal function (tubular secretion physiology) <sup>7</sup>.</p><h4>Characteristics</h4><ul>
- +<li><p>photon energy: 140 KeV</p></li>
- +<li><p>physical half-life: 6 hours</p></li>
- +<li><p>biological half-life: 4 hours</p></li>
- +<li><p>technetium oxidation state: +5</p></li>
- +<li><p>normal distribution: kidneys (100%)</p></li>
- +<li>
- +<p>pharmacokinetics:</p>
- +<ul>
- +<li><p>uptake by tubular secretion (97%)</p></li>
- +<li><p>first pass filtration 60%</p></li>
-<li>excretion: renal via both glomerular filtration and tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to <a href="/articles/gd-dtpa-labeled-albumin">DTPA</a> scan</li>-<li>target organ: bladder</li>-<li>miscellaneous facts<ul>-<li>good quality images with renal insufficiency</li>-<li>by giving captopril, MAG3 plasma clearance decreases in hypertensive patients with <a href="/articles/renal-artery-stenosis">renal artery stenosis</a> but increases in patients without renal artery stenosis</li>-<li>cannot measure <a href="/articles/estimated-glomerular-filtration-rate">GFR</a> as it is cleared almost entirely by tubular secretion</li>- +<li><p>excretion: renal via both glomerular filtration and tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to <a href="/articles/gd-dtpa-labeled-albumin">DTPA</a> scan</p></li>
- +<li><p>target organ: bladder</p></li>
- +<li>
- +<p>miscellaneous facts</p>
- +<ul>
- +<li><p>good quality images with renal insufficiency</p></li>
- +<li><p>by giving captopril, MAG3 plasma clearance decreases in hypertensive patients with <a href="/articles/renal-artery-stenosis">renal artery stenosis</a> but increases in patients without renal artery stenosis</p></li>
- +<li><p>cannot measure <a href="/articles/estimated-glomerular-filtration-rate">GFR</a> as it is cleared almost entirely by tubular secretion</p></li>
- +<li><p>during labelling, MAG3 is heated to remove S-benzoyl group. The S-benzoyl group is important to maintain the stability of the compound during storage conditions <sup>8</sup>.</p></li>
-</ul><h4>Uses, doses and timings</h4><ul><li>renal study<ul>-<li>adult dose: 296 MBq (8 mCi) IV</li>-<li>paediatric dose: 3.7 MBq/kg (0.10 mCi/kg) (minimum: 14.8 MBq (0.4 mCi)) <sup>5</sup>-</li>-<li>60-sec flow study; then every 5 min for 25 min</li>- +</ul><h4>Uses, doses and timings</h4><ul><li>
- +<p>renal study</p>
- +<ul>
- +<li><p>adult dose: 296 MBq (8 mCi) IV</p></li>
- +<li><p>paediatric dose: 3.7 MBq/kg (0.10 mCi/kg) (minimum: 14.8 MBq (0.4 mCi)) <sup>5</sup></p></li>
- +<li><p>60-sec flow study; then every 5 min for 25 min</p></li>
References changed:
- 8. Technical reports series, No 466. Technetium-99m Radiopharmaceuticals: Manufacture of Kits. 2008. ISBN: 978-92-0-100408-6. <a href="https://www.iaea.org/publications/7867/technetium-99m-radiopharmaceuticals-manufacture-of-kits">International Atomic Energy Agency</a>
Unable to process the form. Check for errors and try again.